Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.lauruslabs.com | |
Market Cap | 23,151.28 Cr. | |
Enterprise Value(EV) | 25,287.60 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 3.49 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 123.20 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.01 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 75.24 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 5.71 | Calculated using Price: 429.55 |
Dividend Yield | 0.47 | Period Ending 2023-03 |
No. of Shares Subscribed | 53.90 Cr. | 538,965,858 Shares |
FaceValue | 2 | |
About Laurus Labs Ltd. | ||
Laurus Labs offers broad and integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. Their major focus areas include anti-retroviral, Hepatitis C and Oncology drugs. |
1 Day |
|
-1.40% |
1 Week |
|
-7.43% |
1 Month |
|
+7.01% |
3 Month |
|
+2.48% |
6 Month |
|
+6.59% |
1 Year |
|
+37.52% |
2 Year |
|
-28.88% |
5 Year |
|
+435.64% |
10 Year |
|
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 14.47 | 18.65 | 18.12 | 11.97 | 6.19 | 15.39 | 45.15 | 28.05 | 21.63 | |
Return on Capital Employed (%) | 13.74 | 16.35 | 16.52 | 13.68 | 8.22 | 14.14 | 39.82 | 25.97 | 22.97 | |
Return on Assets (%) | 4.31 | 6.61 | 8.05 | 6.04 | 3 | 7.34 | 20.87 | 13.09 | 10.89 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 722 | 857 | 1,330 | 1,483 | 1,558 | 1,770 | 2,598 | 3,351 | 4,038 | 4,030 | |
Non Curr. Liab. | 364 | 428 | 132 | 174 | 295 | 214 | 693 | 928 | 1,179 | 1,069 | |
Curr. Liab. | 802 | 884 | 1,121 | 1,307 | 1,424 | 1,692 | 2,457 | 2,681 | 2,432 | 2,945 | |
Minority Int. | 3 | 8 | 11 | 13 | |||||||
Equity & Liab. | 1,888 | 2,169 | 2,584 | 2,964 | 3,278 | 3,676 | 5,751 | 6,968 | 7,660 | 8,058 | |
Non Curr. Assets | 1,024 | 1,166 | 1,444 | 1,716 | 1,815 | 1,864 | 2,676 | 3,623 | 4,199 | 4,390 | |
Curr. Assets | 862 | 1,003 | 1,140 | 1,248 | 1,463 | 1,812 | 3,075 | 3,345 | 3,462 | 3,668 | |
Misc. Exp. not W/O | 2 | ||||||||||
Total Assets | 1,888 | 2,169 | 2,584 | 2,964 | 3,278 | 3,676 | 5,751 | 6,968 | 7,660 | 8,058 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 1,327 | 1,778 | 1,905 | 2,056 | 2,292 | 2,832 | 4,814 | 4,936 | 6,041 | 4,982 | |
Other Income | 34 | 4 | 33 | 29 | 16 | 6 | 24 | 15 | 6 | 10 | |
Total Income | 1,361 | 1,782 | 1,938 | 2,085 | 2,308 | 2,838 | 4,837 | 4,951 | 6,047 | 4,992 | |
Total Expenditure | -1,131 | -1,415 | -1,497 | -1,643 | -1,936 | -2,267 | -3,263 | -3,513 | -4,448 | -4,161 | |
PBIDT | 229 | 367 | 441 | 443 | 372 | 570 | 1,574 | 1,438 | 1,598 | 831 | |
Interest | -101 | -111 | -100 | -80 | -88 | -90 | -68 | -102 | -165 | -186 | |
Depreciation | -62 | -86 | -106 | -125 | -164 | -187 | -205 | -251 | -324 | -369 | |
Taxation | 2 | -35 | -44 | -70 | -26 | -38 | -317 | -251 | -312 | -76 | |
Exceptional Items | |||||||||||
PAT | 68 | 134 | 191 | 168 | 94 | 255 | 984 | 832 | 797 | 200 | |
Minority Interest | 0 | -5 | -3 | -5 | |||||||
Share Associate | 0 | 0 | -1 | 0 | -3 | -8 | |||||
Other Related Items | -6 | ||||||||||
Consolidated Net Profit | 68 | 134 | 190 | 168 | 94 | 255 | 984 | 828 | 785 | 188 | |
Adjusted EPS | 2 | 4 | 4 | 3 | 2 | 5 | 18 | 15 | 15 | 3 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 121 | -65 | 182 | 332 | 342 | 298 | 347 | 733 | 911 | 994 | |
Cash Fr. Inv. | -312 | -397 | -312 | -289 | -384 | -253 | -221 | -941 | -914 | -996 | |
Cash Fr. Finan. | 203 | 486 | 103 | -54 | 42 | -45 | -128 | 255 | 30 | -27 | |
Net Change | 12 | 24 | -27 | -10 | 1 | 0 | -1 | 47 | 27 | -29 | |
Cash & Cash Eqvt | 15 | 40 | 13 | 2 | 3 | 3 | 2 | 48 | 75 | 46 |
Thu, 18 Apr 2024
Board Meeting Intimation LAURUS LABS LIMITED has informed the Exchange about Board Meeting to be held on 25-Apr-2024 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2024 and Dividend. |
Thu, 18 Apr 2024
Analysts/Institutional Investor Meet/Con. Call Updates Laurus Labs Limited has informed the Exchange about Schedule of meet |
Sat, 13 Apr 2024
Updates Laurus Labs Limited has informed the Exchange regarding 'Incorporation of a Joint Venture Company in India'. |
Thu, 18 Apr 2024 |
Close Within 52 Week High Zone |
Making Higher Highs for 2 Days |
High Increase in 1 Month |
High Increase in 1 Year |
High Increase in 5 Years |